Aarey Drugs & Pharmaceuticals Clarifies Financial Results Mismatch
Aarey Drugs & Pharmaceuticals Limited submitted revised financial results for the quarter ended December 31, 2025, due to a clerical error causing a mismatch in PAT figures. The revised results were uploaded on April 11, 2026.
This is a routine clarification of a clerical error in financial reporting and does not involve new financial performance data, corporate actions, or strategic changes that would significantly impact the company's stock.
The announcement is a clarification regarding a clerical error in previously submitted financial results. While it corrects an issue, it does not introduce new positive or negative financial information.
Aarey Drugs & Pharmaceuticals Limited has submitted a clarification to the National Stock Exchange of India regarding a mismatch in the Profit After Tax (PAT) figures between the PDF and XBRL submissions of their financial results, which were initially submitted on February 11, 2026. The company attributes this discrepancy to an inadvertent clerical error.
To rectify this, Aarey Drugs & Pharmaceuticals Limited has uploaded revised Integrated Financial Results in the prescribed utility format. The acknowledgement number for this revised submission is 150465, and it was submitted on April 11, 2026. The company requests that these revised results be taken on record.
The financial results pertain to the quarter ended December 31, 2025. The clarification was issued by Nimit Ghatalia, Director, on April 14, 2026.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other results related. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.